Experience

Entropy Bio

• Biotechnology Research
• 1 - 100 Employee

• Founder and Chief Operating Officer

  • Sep 2021 - 2 years 4 months

  United States At Entropy Bio, we are dedicated to discovering and developing the most impactful and advanced therapeutics for rare disease and cancer by seeking the root cause of disease, exploiting the recent explosion of biological knowledge, and fueling experienced teams with predictive platforms and infrastructure to innovate.



Healthtech Solutions, Inc.

• Medical Equipment Manufacturing
• 1 - 100 Employee

• Chief Operating Officer

  • Jul 2021 - Sep 2021

  New York City Metropolitan Area



argenx

• United States
• Biotechnology Research
• 700 & Above Employee

• Head of The US Neurology Franchise

  • Nov 2019 - Feb 2021

  Boston, Massachusetts, United States



Orchard Therapeutics

• United Kingdom
• Biotechnology
• 100 - 200 Employee

• Vice President & GM, US Commercial Operations

  • Jun 2018 - Nov 2019

  Boston, MA Orchard Therapeutics is a clinical stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies. Our vision is to become the leader in gene therapy for primary immune deficiencies and inherited metabolic disorders.



Sucampo Pharmaceuticals, Inc. (Acquired by Mallinckrodt Pharma)

• VP & GM, Head of US Commercial

  • Aug 2017 - Apr 2018

  Rockville, MD Developed successful commercialization and launch plans for VTS-270 for NPC, a lysosomal storage disorder. Led on-going build-out and management of US customer-facing functions. Developed and executed strategic sales plan as well as hired and established US commercial field positions within sales, marketing, market access, diagnostics, and clinical thought leaders. Prepared the market for the launch of VTS-270 for NPC prior to corporate acquisition by Mallinckrodt Pharmaceuticals in April… Show more Developed successful commercialization and launch plans for VTS-270 for NPC, a lysosomal storage disorder. Led on-going build-out and management of US customer-facing functions. Developed and executed strategic sales plan as well as hired and established US commercial field positions within sales, marketing, market access, diagnostics, and clinical thought leaders. Prepared the market for the launch of VTS-270 for NPC prior to corporate acquisition by Mallinckrodt Pharmaceuticals in April 2018. Through strategic data analysis I led the identification of 287 patients, exceeding acquisition target estimate at peak sales prior to launch. Oversaw strategic diagnostic project to add NPC to newborn screening panel (RUSP) for all babies born in US. Delivered fully executable business plans for launch of VTS 270. Presented launch plan to the Board of Directors highlighting Strategic Pillars and Critical Initiatives regarding patient identification, ensuring access to high quality testing and establishing US Salesforce size and structure. Leveraged key relationships with the NIH to support better understanding of the patient journey and inform on opportunities to educate resulting in improved diagnostics for early diagnosis and intervention. Show less



Alexion Pharmaceuticals, Inc.

• United States
• Biotechnology Research
• 700 & Above Employee

• Executive Director of US Sales

  • Sep 2015 - Aug 2017

  Greater New York City Area Managed team of six regional directors and 42 regional managers to achieve and exceed sales targets for complement franchise calling on hematologists, nephrologists, hospitalists, hematopathologists, and intensivists for indications of PNH and aHUS. Collaborated closely with US marketing teams to impact marketing plans. Drove US marketing plan through key strategy and tactics by identifying patients, generating demand, creating access, and supporting appropriate utilization. Managed annual… Show more Managed team of six regional directors and 42 regional managers to achieve and exceed sales targets for complement franchise calling on hematologists, nephrologists, hospitalists, hematopathologists, and intensivists for indications of PNH and aHUS. Collaborated closely with US marketing teams to impact marketing plans. Drove US marketing plan through key strategy and tactics by identifying patients, generating demand, creating access, and supporting appropriate utilization. Managed annual budget for area and regional US sales team. Executed and oversaw regional quarterly business reviews as well as served in quarterly executive business reviews. Assembled team and staffed regional sales directors and regional account managers. Led team to deliver $1,600,000,000 in annual revenue and double-digit growth. Achieved area US sales performance targets through development and execution of strategic/tactical regional sales plans. Delivered highest record quarter ever in newly identified and net new patients since launch Q2, 2016. Actively reviewed performance metrics with sales directors to ensure sales team achieved maximum sales results from assigned territories. Established favorable and on-going partnership with patient access services support team and STAR team partners to ensure success of Soliris and patients’ access to therapy. Ensured appropriate leadership and development of team by defining clear objectives, allocating resources, monitoring activities, distributing fair rewards and sales incentive plans, as well as providing developmental opportunities.

• Sr. Director, Market Access

  • Oct 2013 - Sep 2015

  Developed, implemented and influenced collaborative to ensure access to Soliris (Eculizumab) for ultra-orphan population of patients with PNH, aHUS and Asfotase Alfa for HPP. Created and led top-performing national team executing ultra-orphan business strategy with regards to payers, PBMs and SPP for all approved indications. Aligned business strategy and plans to provide support for case management and patients in overturning denials and restrictive funding criteria, including development… Show more Developed, implemented and influenced collaborative to ensure access to Soliris (Eculizumab) for ultra-orphan population of patients with PNH, aHUS and Asfotase Alfa for HPP. Created and led top-performing national team executing ultra-orphan business strategy with regards to payers, PBMs and SPP for all approved indications. Aligned business strategy and plans to provide support for case management and patients in overturning denials and restrictive funding criteria, including development and implementation of coverage policies for Soliris (Eculizumab) for PNH or aHUS. Created HEOR story with medical affairs using premier database to prove Soliris as cost-effective option in hospital. Demonstrated $100,000 in savings per patient by using Soliris to quickly address disease. Collaborated with pharmacy to start therapy, saving patients’ lives. Led development and implementation of strategic planning to ensure payer program criteria are favorable for access to Alexion products with unified message supporting appropriate use backed by clinical resources. Actively engaged medical affairs to develop clinical strategies to support access to Soliris and Asfotase Alfa for appropriate patients. Collaborated with government affairs to ensure support/coverage for public payers, including Medicare, Medicaid, and 340B. Acted as team lead for access and reimbursement in launch team planning, including partnership development with customer operations to enable access to Asfotase Alfa, ensuring flawless execution of HPP launch plan through specialty pharmacy distribution channel.

• Sr. Director; US Marketing, Nephrology

  • Nov 2011 - Oct 2013

  Cheshire, CT Managed team of directors, associate directors and senior managers to execute strategic objectives for market development, indication growth and patient retention strategy. Focused brand strategy on digital, non-personal, patient(DTC) and HCP Nephrology Specialty. Managed $12,500,000 budget. Oversaw situational assessment development, strategic plan development, tactical plan creation and quarterly presentations to CEO and CFO regarding comprehensive business updates. Led US nephrology… Show more Managed team of directors, associate directors and senior managers to execute strategic objectives for market development, indication growth and patient retention strategy. Focused brand strategy on digital, non-personal, patient(DTC) and HCP Nephrology Specialty. Managed $12,500,000 budget. Oversaw situational assessment development, strategic plan development, tactical plan creation and quarterly presentations to CEO and CFO regarding comprehensive business updates. Led US nephrology marketing launch for Soliris second indication for aHUS to most successful ultra-orphan launch in US history. Developed and led genetic testing project for patients with AHUS, resulting in collaborative partnership with key academic institutions Washington University in St. Louis Identified solution for share of voice by placing primary focus on hematologists as they prescribed majority of product. Rolled all of marketing together as best structure for business. Worked with FDA and legal team to develop/promote supporting materials to ensure corporate compliance despite restrictive conditions under accelerated approval. Conducted weekly assessment of US KPI metrics for performance and analysis, delivering on all metrics.

• Director of Global Training and Development

  • Sep 2009 - Nov 2011

  Cheshire, CT Oversaw training department. Managed global infrastructure for training and development across 50 countries, supporting clinical training for Soliris in PNH and aHUS. Served as global trainer. Built and executed comprehensive module system to standardized training curriculum. Led through continuum from development to implementation of sales training modules. Adapted training content and materials for Japan, Brazil, Argentina, France, Germany, Spain, EMEA and the Nordics. Worked with medical… Show more Oversaw training department. Managed global infrastructure for training and development across 50 countries, supporting clinical training for Soliris in PNH and aHUS. Served as global trainer. Built and executed comprehensive module system to standardized training curriculum. Led through continuum from development to implementation of sales training modules. Adapted training content and materials for Japan, Brazil, Argentina, France, Germany, Spain, EMEA and the Nordics. Worked with medical to develop scientific platform. Presented data and conducted training classes. Hired and developed US/international Trainers which included four in US and one in Switzerland. Initiated and executed LMS project identification and implementation to support assessment/accountability of clinical training worldwide. Developed global footprint for world-class training department. Won chairman's award of excellence for exceptional performance.

• Regional Sales Director

  • Jan 2007 - Sep 2009

  Central United States Led team of eight regional account managers covering central US from Texas to Michigan for launch of first indication in hematology. Managed team to achieve corporate objectives to identify new patients, create access, and support appropriate utilization. Oversaw strategic planning and execution of sales plans. Established appropriate relationships with KOL audience. Supported resource allocation as well as continued growth and development through clinical acumen, business acumen and… Show more Led team of eight regional account managers covering central US from Texas to Michigan for launch of first indication in hematology. Managed team to achieve corporate objectives to identify new patients, create access, and support appropriate utilization. Oversaw strategic planning and execution of sales plans. Established appropriate relationships with KOL audience. Supported resource allocation as well as continued growth and development through clinical acumen, business acumen and appropriate coaching. Served as mentor for new regional sales manager hires. Acted as regional sales director lead for field diagnostics team initiatives. Led team through three US expansions. Consistently met or exceeded corporate objectives.



Bristol Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Sr Sales Manager

  • Mar 2005 - Jan 2007

  South West Region Responsibilities included hiring the initial sales team for the launch of Orencia, a biologic for RA. Position reported to the Vice President of Sales, Southwest Region.



Biogen

• United States
• Biotechnology Research
• 700 & Above Employee

• Regional Sales Manager

  • 2002 - 2005

  Regional Sales Manager for a team of Sales Representatives selling a biologic for Psoriasis. The product was sold off in 2005.